Cost-effectiveness of combination fluticasone propionate-salmeterol 250/50 microg versus salmeterol in severe COPD patients.

International journal of chronic obstructive pulmonary disease

Volumn 5, Issue , 2010, Pages 179-187

  Dalal, Anand A ^a   St Charles, Meaghan ^b   Petersen, Hans V ^b   Roberts, Melissa H ^b   Blanchette, Christopher M ^b   Manavi Zieverink, Kathy ^b  

^a GLAXOSMITHKLINE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANDROSTANE DERIVATIVE; BRONCHODILATING AGENT; DRUG DERIVATIVE; FLUTICASONE, SALMETEROL DRUG COMBINATION; SALBUTAMOL; SALMETEROL;

AGED; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMPARATIVE STUDY; COST BENEFIT ANALYSIS; DRUG COMBINATION; ECONOMICS; FEMALE; HOSPITALIZATION; HUMAN; MALE; MIDDLE AGED; PATHOPHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL (TOPIC);

AGED; ALBUTEROL; ANDROSTADIENES; BRONCHODILATOR AGENTS; COST-BENEFIT ANALYSIS; DRUG COMBINATIONS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MIDDLE AGED; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEVERITY OF ILLNESS INDEX;

EID: 79952023002     PISSN: None     EISSN: 11782005     Source Type: Journal    
DOI: None     Document Type: Article

References (0)